Biotech Values

[lgonber]

AAVL. If there is good data, I don't se why the stock will sell off. The trial most probably will meet primary endpoint and show it is safe. Moreover although the trial is not designed to power that,should have an efficacy signal (reduction in frequency of anti- VEGF administration). If that is the case, I would expect the price to be much higher than what it is now.